Evidence map›Paper›PMID 38001658›Full record

ReviewCancers2023

Breast Cancer in the Arabian Gulf Countries.

Humaid O Al-Shamsi, Nadia Abdelwahed, Amin Abyad, Ibrahim Abu-Gheida, Mehdi Afrit, Tasneem Abu ElFuol, Ryad Alasas, Bilal Lababidi, Prasanta Dash, Mudhasir Ahmad and 16 more

Abstract readReview
In one paragraph

Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Cancer Genetics in the Arab World.Technology in cancer research & treatment
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Humaid O Al-ShamsiBurjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates.ORCID 0000-0003-3819-0500
Nadia AbdelwahedBurjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates.
Amin AbyadBurjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates.
Ibrahim Abu-GheidaBurjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates.
Mehdi AfritBurjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates.
Tasneem Abu ElFuolBurjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates.
Ryad AlasasBurjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates.
Bilal LababidiBurjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates.
Prasanta DashBurjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates.
Mudhasir AhmadBurjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates.
Norbert W DreierBurjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates.
Urfan Ul HaqBurjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates.
Thanda Lucy Ann JoshuaBurjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates.
Sonia OtsmaneBurjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates.
Anwar Al-NouriKuwait Cancer Control Center, Kuwait City, Kuwait.
Aydah Al-AwadhiEmirates Oncology Society, Dubai P.O. Box 6600, United Arab Emirates.
Syed Hammad TirmazyDubai Hospital, Dubai P.O. Box 7272, United Arab Emirates.
Faisal AlterkaitKuwait Cancer Control Center, Kuwait City, Kuwait.
Shimaa ElsabaeBurjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates.
Nyla KhanBurjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates.
Nehad Kazim AlbastakiBurjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates.
Yoginee SonawaneBurjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates.
Mohammed JoudaBurjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates.
Frea PerdawoodBurjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates.
Faryal IqbalBurjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates.
Hassan JaafarBurjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer stands as the prevailing malignancy across all six Gulf Cooperation Council (GCC) nations. In this literature review, we highlighted the incidence and trend of breast cancer in the GCC. Most of the studies reported a consistent increase in breast cancer incidence over the past decades, which was particularly attributed to the adoption of a Westernized lifestyle in the region and the implications of emerging risk factors and other environmental and societal factors, the increase in screening uptake, as well as the improvement in data collection and reporting in the GCC. The data on breast cancer risk factors in the GCC were limited. In this geographic region, breast cancer frequently manifests with distinctive characteristics, including an early onset, typically occurring before the age of 50; an advanced stage at presentation; and a higher pathological grade. Additionally, it often exhibits more aggressive features such as human epidermal growth factor receptor 2 (HER2) positivity or the presence of triple-negative (TN) attributes, particularly among younger patients. Despite the growing body of literature on breast cancer in the GCC, data pertaining to survival rates are, regrettably, meager. Reports on breast cancer survival rates emanating from the GCC region are largely confined to Saudi Arabia and the United Arab Emirates (UAE). In the UAE, predictive modeling reveals 2-year and 5-year survival rates of 97% and 89%, respectively, for the same period under scrutiny. These rates, when compared to Western counterparts such as Australia (89.5%) and Canada (88.2%), fall within the expected range. Conversely, Saudi Arabia reports a notably lower 5-year survival rate, standing at 72%. This disparity in survival rates underscores the need for further research directed toward elucidating risk factors and barriers that hinder early detection and screening. Additionally, there is a pressing need for expanded data reporting on survival outcomes within the GCC. In sum, a more comprehensive and nuanced understanding of breast cancer dynamics in this region is imperative to inform effective strategies for prevention, early detection, and improved patient outcomes.

Indexed as

breast cancerGulf Cooperation Council (GCC)HER2malignancysurvivaltriple negative

Identifiers

PMID38001658
PMCPMC10670541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.